Blog
RSS FeedPosted by Michael Wonder on 08 Feb 2017
Health Canada approves Gazyva for patients with previously treated follicular lymphoma
7 February 2017 - Roche Canada today announced that Health Canada has approved Gazyva (obinutuzumab) in combination with bendamustine followed ...
Posted by Michael Wonder on 01 Feb 2017
Sanofi and Regeneron announce first approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients by Health Canada
1 February 2017 - Regulatory decisions for Kevzara are anticipated in the United States and European Union later this year. ...
Posted by Michael Wonder on 25 Jan 2017
Health Canada approves Revlimid plus dexamethasone as a first-line treatment for patients newly diagnosed with multiple myeloma, not eligible for transplant
24 January 2017 - Celgene announced today that Health Canada has expanded the indication for Revlimid (lenalidomide capsules), in multiple myeloma. ...
Posted by Michael Wonder on 12 Jan 2017
Health Canada approves new heart failure treatment Lancora to reduce mortality and hospitalisations
10 January 2017 - Health Canada has issued a Notice of Compliance for Lancora (ivabradine hydrochloride), a new treatment shown to ...
Posted by Michael Wonder on 09 Jan 2017
BioCryst receives Health Canada approval for Rapivab for the treatment of influenza
8 January 2017 - BioCryst Pharmaceuticals today announced that Health Canada has approved Rapivab (peramivir injection), an intravenous treatment for ...
Posted by Michael Wonder on 05 Jan 2017
Health Canada approves Orfadin capsules for treatment of hereditary tyrosinaemia type-1
4 January 2017 - Orfadin to be available in a range of dosing alternatives, including first ever 20 mg dosage. ...
Posted by Michael Wonder on 15 Dec 2016
Health Canada approves Stelara for the treatment of adults with moderately to severely active Crohn's disease
14 December 2016 - Stelara offers a new approach to treating Crohn's disease in Canada, which has one of the ...
Posted by Michael Wonder on 15 Dec 2016
Health Canada approves CSL Behring’s Afstyla for the treatment of haemophilia A
14 December 2016 - Afstyla is the first and only single-chain recombinant factor VIII for haemophilia A, specifically designed for ...
Posted by Michael Wonder on 14 Dec 2016
New formulation of Rituxan now available to Canadians living with non-Hodgkin's lymphoma
13 December 2016 - Canadians living with non-Hodgkin's lymphoma, one of the most commonly diagnosed blood cancers in Canada, now have ...
Posted by Michael Wonder on 13 Dec 2016
Pediapharm receives Health Canada approval for Otixal
12 December 2016 - Pediapharm is very pleased to announce Health Canada's approval of Otixal (ciprofloxacin 0.3 % and fluocinolone ...
Posted by Michael Wonder on 13 Dec 2016
Emergent BioSolutions receives Health Canada approval for botulism anti-toxin
12 December 2016 - Emergent BioSolutions today announced that Health Canada has approved the company’s new drug submission for its botulism ...
Posted by Michael Wonder on 09 Dec 2016
Biogen and AbbVie receive Health Canada approval of once monthly Zinbryta (daclizumab beta) for multiple sclerosis
9 December 2016 - Approval supported by largest and longest head-to-head global Phase 3 study conducted in multiple sclerosis. ...
Posted by Michael Wonder on 26 Nov 2016
Important new cancer treatments approved by Health Canada marred by major provincial reality disconnect for patients
22 November 2016 - Health Canada recently conditionally approved an advanced new treatment option for Canadians battling metastatic melanoma. ...
Posted by Michael Wonder on 22 Nov 2016
Allergan announces receipt of additional Health Canada approval for Fibristal
21 November 2016 - Allergan announced that it has received an additional approval from Health Canada for Fibristal (ulipristal acetate, 5 ...
Posted by Michael Wonder on 15 Nov 2016
Once-daily anticoagulant Lixiana (edoxaban tosylate) approved in Canada for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrent deep-vein thrombosis and pulmonary embolism
9 November 2016 - Servier Canada announced today that Lixiana (edoxaban tosylate) has been approved by Health Canada for the two ...